Innovation Kyoto 2021 Investment Limited Partnership" ("KYOTO-icap No.2 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Kimi Kusumi) as the general partner, has made a new investment in Cellshute Therapeutics Co. (headquartered in Koto-ku, Tokyo; Hiroshi Tanaka and Noriyuki Masuda, co-presidents).

Outline of this investment
Cell Shoot Therapeutics was established in July 2021 and is a drug discovery venture with a platform based on the PLOM-CON analysis method for spatio-temporal and comprehensive analysis of intracellular protein networks invented by Masayuki Murata, Specially Appointed Professor Emeritus at the Tokyo Institute of Technology, and Fumi Kano, Associate Professor at the University of Tokyo, and the semi-intact cell The company is a drug discovery venture with a platform based on the PLOM-CON analysis method for spatio-temporal and comprehensive analysis of intracellular protein networks and the semi-intact cell reseal method for reproducing pathological conditions.

The cells that make up the human body are composed of more than several thousand different types of proteins and lipid molecules, and can be compared to precision machines. The PLOM-CON analysis method is a new technique that enables us to simultaneously stain a large number of molecules, image them continuously, analyze their relationships, and illustrate them with indicators of their importance. PLOM-CON analysis enables the discovery of important molecules in living organisms that were previously unknown, and the creation of pharmaceuticals targeting these molecules is expected. The semi-intact cell reseal method can also be used to artificially reproduce diseased cells, which can be combined with PLOM-CON analysis to identify new disease-specific drug targets.

Kyoto iCAP has made a new investment of 100 million yen through a third-party allocation of new shares in the hope that CellSute Therapeutics will discover unknown drug targets through its proprietary platform technology and create drugs with a new mechanism of action. In addition to Kyoto iCAP, the new financing totaled 230 million yen, with participation from a limited liability investment partnership managed by Fast Track Initiative Inc. and a limited liability investment partnership managed by SMBC Venture Capital Co. The total amount of funds raised by the company since its inception is approximately 380 million yen.

Overview of CellSute Therapeutics, Inc.

Establishment	July 2021
Business	Exploration of drug target molecules and discovery of new drugs using intracellular protein pathway analysis
Head Office Location	Koto-ku, Tokyo
President & CEO	(Co-Chairs) Hiroshi Tanaka, Noriyuki Masuda
uniform resouce locator	https://cellshoot.co.jp/